India is grappling with a growing superbug crisis, where antibiotic-resistant infections are becoming harder to treat. Misuse and lack of access to life-saving antibiotics are driving the problem. A global study reveals only 6.9% of patients in low- and middle-income countries, including India, receive effective treatment. High costs, poor diagnostics, and weak regulation worsen the issue. Experts warn that without better antibiotic access and control, routine treatments, surgeries, and cancer care could be jeopardized. India’s strong pharma sector could lead solutions with better data and policy.